Krishna Institute of Medical Sciences Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Fri Apr 24 2026

Krishna Institute of Medical Sciences (KIMS) is set to announce its Q4 FY26 results in May 2026. Investors and market participants are keenly watching the upcoming quarterly numbers for one of India’s well-known Healthcare and Diagnostics companies. The Q4 FY26 earnings season is a critical period for equity markets as full-year financial performance comes into sharper focus.

Analyst consensus estimates project Krishna Institute of Medical Sciences Q4 FY26 revenue at Rs 520 Cr, representing a year-on-year growth of approximately 8%, while PAT is estimated at Rs 100 Cr, a growth of approximately 14% compared to the same quarter in FY25. These estimates reflect the sector outlook and company-specific operational momentum observed over the preceding quarters.

In this article, we provide a detailed preview of Krishna Institute of Medical Sciences Q4 results 2026, including the expected date, key financial estimates, five growth factors, five risks and the latest analyst ratings. Get free investment insights on Univest to stay ahead of earnings season.

Table of Contents

Krishna Institute of Medical Sciences Q4 Results 2026 Date

Access premium research and earnings previews on Univest before every major result announcement.

The Krishna Institute of Medical Sciences Q4 FY26 results are expected to be declared in May 2026. The board of directors will convene a meeting to approve the audited financial results for the quarter and full year ended March 31, 2026. The exact date will be intimated through BSE and NSE filings. Investors should monitor exchange announcements for the confirmed date.

Company	Q4 Results Date	Key Watch
TCS	April 9, 2026	Revenue growth and deal wins
Infosys	April 23, 2026	FY27 guidance and margin outlook
Krishna Institute of Medical Sciences	May 2026 (Expected)	Revenue, PAT and dividend announcement

Why This Quarter Matters for Krishna Institute of Medical Sciences

India’s healthcare diagnostics sector maintains solid growth momentum in Q4 FY26, backed by rising health awareness, insurance penetration expansion and a robust preventive testing trend driving test volumes across the country.

For Krishna Institute of Medical Sciences specifically, Q4 FY26 is a critical quarter as it determines the full-year FY26 performance trajectory. The management’s commentary on FY27 outlook, any guidance revision and dividend announcement will be equally important for investor sentiment as the headline revenue and PAT numbers.

Krishna Institute of Medical Sciences Q4 FY26 Earnings Estimates

Screen Krishna Institute of Medical Sciences fundamentals, historical financials and technical indicators on Univest Screener.

Based on analyst consensus and sector-level research, Krishna Institute of Medical Sciences is expected to report Q4 FY26 revenue of Rs 520 Cr, up 8% year-on-year. PAT is estimated at Rs 100 Cr, reflecting 14% growth. EBITDA margin is expected to come in at approximately 19.2%, showing improvement compared to the year-ago quarter driven by operating leverage and cost efficiencies.

Metric	Q3 FY26 (Actual)	Q4 FY26 (Estimate)	YoY Change
Revenue (Rs Cr)	480	520	+8% (Est)
PAT (Rs Cr)	88	100	+14% (Est)
PAT Margin (%)	18.3%	19.2%	Expanding
Dividend History	Rs 4.00 per share		–
Dividend Expectation	Rs 5.00 final dividend expected		–

Beyond the headline numbers, key metrics to watch include EBITDA margin trajectory, working capital management, order book or pipeline commentary and management guidance for FY27. These forward-looking indicators often have a larger impact on stock price reaction than the reported PAT figure alone.

Track Krishna Institute of Medical Sciences fundamentals and compare it with sector peers on Univest Screener for in-depth financial analysis.

5 Key Factors That Will Drive Krishna Institute of Medical Sciences Q4 FY26 Performance

1. Preventive Healthcare Demand

Growing health consciousness and rising insurance coverage are driving strong demand for health checkup packages and chronic disease monitoring tests, both of which carry higher margins.

2. Network Expansion into Tier-2 and Tier-3 Cities

Diagnostic chains are capturing untapped demand in semi-urban India through hub-and-spoke lab models and home collection services, expanding addressable market significantly.

3. Specialised Testing Growth

High-value testing in genomics, immunology, molecular diagnostics and oncology is growing rapidly, improving revenue per patient and blended margin profiles.

4. Institutional and B2B Business

Tie-ups with hospitals, corporates and insurance companies for dedicated diagnostic services create stable, recurring B2B revenue with lower customer acquisition costs.

5. Digital Health Platform Integration

Digital booking, home collection and online reporting platforms are improving patient experience, loyalty and repeat testing rates, reducing churn and acquisition costs.

5 Risks to Watch in Krishna Institute of Medical Sciences Q4 FY26

1. Price War from Competition

Aggressive discounting by unorganised labs and newer entrant chains pressures realisations and tests-per-patient metrics across markets.

2. Regulatory Quality Requirements

NABL accreditation maintenance, CGHS panel compliance and quality audits add ongoing operational costs that weigh on margins.

3. Capital Intensity of Network Expansion

Setting up new collection centres and processing labs requires significant capital; ROI typically takes 2-3 years to fully materialise.

4. Equipment Upgrade Capex

Rapid diagnostic technology evolution requires continuous equipment replacement investment, adding recurring capex pressure.

5. Insurance Reimbursement Pressure

Health insurers negotiating lower reimbursement rates for diagnostic tests can reduce revenue per test over time.

Krishna Institute of Medical Sciences Share Price and Analyst Ratings

Krishna Institute of Medical Sciences (KIMS) is currently trading at Rs 1780 with a market capitalisation of approximately Rs 12,100 Cr. The stock has been under investor scrutiny ahead of Q4 results, with analysts closely monitoring sector trends and company-specific developments that could influence the quarterly outcome.

Brokerage	Rating	Target Price	Thesis
Emkay Global	Buy	Rs 2100	Network expansion and volume recovery on track
JM Financial	Neutral	Rs 1869	Competition intensity remains a concern
ICICI Direct	Buy	Rs 2100	Preventive health demand and B2B growth drivers

Download the Univest iOS App or the Univest Android App to track Krishna Institute of Medical Sciences share price, analyst ratings and earnings updates in real time.

Conclusion

Krishna Institute of Medical Sciences heads into Q4 FY26 with reasonable earnings visibility, supported by sector tailwinds and company-specific operational improvements. The Q4 numbers will be an important validation of the full-year FY26 investment thesis. Investors should track the results date, dividend announcement and management commentary on FY27 guidance closely. For ongoing research and stock insights, visit Univest Blogs.

This article is for informational and educational purposes only and does not constitute investment advice. All estimates are based on publicly available analyst research and are subject to change. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

What is the Krishna Institute of Medical Sciences Q4 results 2026 date?

The Krishna Institute of Medical Sciences Q4 FY26 results are expected to be announced in May 2026. The exact date will be confirmed by the company’s board through a BSE and NSE filing. Check Univest for real-time updates.

What is the Krishna Institute of Medical Sciences Q4 FY26 PAT estimate?

Analyst consensus estimates put Krishna Institute of Medical Sciences Q4 FY26 PAT at approximately Rs 100 Cr, representing a year-on-year growth of approximately 14% compared to the same quarter in FY25. These are estimates and actual results may vary.

What is Krishna Institute of Medical Sciences share price ahead of Q4 results?

Krishna Institute of Medical Sciences share price (ticker: KIMS) is trading near Rs 1780 with a market capitalisation of approximately Rs 12,100 Cr. Investors should track the stock on Univest Screener for live price and fundamental data.

Will Krishna Institute of Medical Sciences declare a dividend in Q4 2026?

Based on available analyst estimates and historical dividend patterns, Rs 5.00 final dividend expected. Krishna Institute of Medical Sciences’s historical dividend record shows Rs 4.00 per share. A final dividend announcement is typically made at the board meeting where Q4 results are declared.

Which analysts have a Buy rating on Krishna Institute of Medical Sciences?

Based on publicly available brokerage research, Emkay Global has a Buy rating on Krishna Institute of Medical Sciences with the thesis: Network expansion and volume recovery on track. Ratings are subject to change; always consult a SEBI-registered advisor before investing.

What were Krishna Institute of Medical Sciences Q3 FY26 results?

Krishna Institute of Medical Sciences reported Q3 FY26 revenue of Rs 480 Cr and PAT of Rs 88 Cr. The management commentary highlighted key operational metrics and sector-specific guidance that set the expectations benchmark for Q4 FY26 performance.

When do Infosys and TCS announce Q4 results 2026?

TCS announced its Q4 FY26 results on April 9, 2026, while Infosys announced on April 23, 2026. These results set the broader IT sector tone and benchmark for Q4 earnings season.

Is Krishna Institute of Medical Sciences a good investment ahead of Q4 results?

Krishna Institute of Medical Sciences operates in the Healthcare and Diagnostics sector and its Q4 FY26 performance will be determined by the factors outlined above. Any investment decision should be based on your personal financial goals, risk tolerance and a consultation with a SEBI-registered investment advisor. Access research on Univest.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE and BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.